Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients (Q39266110)

10 September 2017

title

Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients (English)

1 reference

10 September 2017

Rudolph M Navari

1 reference

10 September 2017

publication date

21 April 2017

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

1 reference

10 September 2017

page(s)

213-222

1 reference

Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

2016 updated MASCC/ESMO consensus recommendations: Prevention of acute chemotherapy-induced nausea and vomiting in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Antiemetics in children receiving chemotherapy. MASCC/ESMO guideline update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Evidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

The current status of the use of palonosetron

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Palonosetron for the treatment of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

The Safety of Metoclopramide in Children: A Systematic Review and Meta-Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Single-Dose Fosaprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting Associated With Cisplatin Therapy: Randomized, Double-Blind Study Protocol—EASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Aprepitant and fosaprepitant: a 10-year review of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Rolapitant for the treatment of chemotherapy-induced nausea and vomiting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Radioreceptor binding profile of the atypical antipsychotic olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

An open trial of olanzapine for the treatment of delirium in hospitalized cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Reduced ghrelin secretion in the hypothalamus of rats due to cisplatin-induced anorexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Lorcaserin: an investigational serotonin 2C agonist for weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

The safety of olanzapine in young children: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-017-0228-2

Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial

21 January 2018

1 reference

12 December 2020

Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)

1 reference

12 December 2020

1 reference

12 December 2020

Psychopharmacology of olanzapine. A review.

1 reference

12 December 2020

[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]

1 reference

12 December 2020

[Study on clinical effect of a continuous intravenous infusion of azasetron against nausea and vomiting induced by anticancer drugs including CDDP]

1 reference

12 December 2020

Aprepitant and fosaprepitant use in children and adolescents at an academic medical center

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood

1 reference

12 December 2020

Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

10.1007/S40272-017-0228-2

Identifiers

DOI

1 reference

10 September 2017

1 reference